331 related articles for article (PubMed ID: 23233654)
1. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.
Umiċeviċ Mirkov M; Cui J; Vermeulen SH; Stahl EA; Toonen EJ; Makkinje RR; Lee AT; Huizinga TW; Allaart R; Barton A; Mariette X; Miceli CR; Criswell LA; Tak PP; de Vries N; Saevarsdottir S; Padyukov L; Bridges SL; van Schaardenburg DJ; Jansen TL; Dutmer EA; van de Laar MA; Barrera P; Radstake TR; van Riel PL; Scheffer H; Franke B; Brunner HG; Plenge RM; Gregersen PK; Guchelaar HJ; Coenen MJ
Ann Rheum Dis; 2013 Aug; 72(8):1375-81. PubMed ID: 23233654
[TBL] [Abstract][Full Text] [Related]
2. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
Zervou MI; Myrthianou E; Flouri I; Plant D; Chlouverakis G; Castro-Giner F; Rapsomaniki P; Barton A; Boumpas DT; Sidiropoulos P; Goulielmos GN
PLoS One; 2013; 8(9):e74375. PubMed ID: 24040234
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.
Coulthard LR; Taylor JC; Eyre S; ; Robinson JI; Wilson AG; Isaacs JD; Hyrich K; Emery P; Barton A; Barrett JH; Morgan AW; McDermott MF
Ann Rheum Dis; 2011 Jan; 70(1):98-103. PubMed ID: 20805296
[TBL] [Abstract][Full Text] [Related]
4. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
[TBL] [Abstract][Full Text] [Related]
5. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
6. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
9. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
10. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
[TBL] [Abstract][Full Text] [Related]
11. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL
Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
Virkki LM; Valleala H; Takakubo Y; Vuotila J; Relas H; Komulainen R; Koivuniemi R; Yli-Kerttula U; Mali M; Sihvonen S; Krogerus ML; Jukka E; Nyrhinen S; Konttinen YT; Nordström DC
Clin Rheumatol; 2011 Nov; 30(11):1447-54. PubMed ID: 21644062
[TBL] [Abstract][Full Text] [Related]
15. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
16. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.
Coenen MJ; Toonen EJ; Scheffer H; Radstake TR; Barrera P; Franke B
Pharmacogenomics; 2007 Jul; 8(7):761-73. PubMed ID: 17638513
[TBL] [Abstract][Full Text] [Related]
18. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
[TBL] [Abstract][Full Text] [Related]
19. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
[TBL] [Abstract][Full Text] [Related]
20. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis.
Krintel SB; Palermo G; Johansen JS; Germer S; Essioux L; Benayed R; Badi L; Ostergaard M; Hetland ML
Pharmacogenet Genomics; 2012 Aug; 22(8):577-89. PubMed ID: 22569225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
